TABLE 2.
Efficacies of NTZ and paromomycin against C. parvum in the neonatal mouse model
| Compound | Compound name | Chemical structure | Dose (mg/kg of body wt)a | Oocyst level (% of control)b (mean ± SE) |
|---|---|---|---|---|
| NTZ | 2-Acetyloxy-N-[(5-nitro-2-thiazolyl)] benzamide |  |
100.0c | 42.3 ± 4.6d |
| 100.0e | 26.0 ± 4.5d | |||
| 150.0ef | 4.3 ± 1.0d | |||
| Paromomycin | O-2-Amino-2-deoxy-α-d-gluco-pyranosyl-(1→4)-O-[O-2,6-diamino-2,6-dideoxy-β-l-idopyranosyl-(1→3)-β-d-ribofuranosyl-(1→5)]-2-deoxy-d-streptamine | 50.0 | 1.2 ± 0.6d |
a
Mice were treated at a constant dose rate daily for 6 days.
b
Mean numbers of oocysts in treated mice are expressed as percentages of the mean number of oocysts recovered from control mice (taken as 100%).
c
Oral formulation.
d
Treated mice and control mice were significantly different (P ≤ 0.05).
e
Injectable formulation administered orally.
f
This dosage appeared moderately toxic; 14 of 25 mice survived the treatment period.